ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Two firms have launched, each with $75 million in funding, to develop radiopharmaceuticals for cancer. Cambridge, Massachusetts–based Curie Therapeutics has emerged from stealth to develop what it says are rationally designed conjugates that deliver α- and β-emitting radionuclide payloads. And Ablaze Pharmaceuticals has launched to bring to China targeted radiopharmaceuticals developed by firms including San Diego’s RayzeBio. Ablaze cofounder Ken Song is also CEO of RayzeBio.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X